These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 21666713)
1. Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Bergamaschi A; Katzenellenbogen BS Oncogene; 2012 Jan; 31(1):39-47. PubMed ID: 21666713 [TBL] [Abstract][Full Text] [Related]
2. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis. Bergamaschi A; Christensen BL; Katzenellenbogen BS Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964 [TBL] [Abstract][Full Text] [Related]
3. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators. Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143 [TBL] [Abstract][Full Text] [Related]
4. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. Li J; Lu M; Jin J; Lu X; Xu T; Jin S Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449 [TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. Fan P; Craig Jordan V Steroids; 2014 Nov; 90():44-52. PubMed ID: 24930824 [TBL] [Abstract][Full Text] [Related]
6. Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy. Liu ZR; Song Y; Wan LH; Zhang YY; Zhou LM Life Sci; 2016 Mar; 149():104-13. PubMed ID: 26896688 [TBL] [Abstract][Full Text] [Related]
7. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Cittelly DM; Das PM; Salvo VA; Fonseca JP; Burow ME; Jones FE Carcinogenesis; 2010 Dec; 31(12):2049-57. PubMed ID: 20876285 [TBL] [Abstract][Full Text] [Related]
8. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881 [TBL] [Abstract][Full Text] [Related]
9. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905 [TBL] [Abstract][Full Text] [Related]
10. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Howell SJ; Johnston SR; Howell A Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Lewis-Wambi JS; Jordan VC Breast Dis; 2005-2006; 24():93-105. PubMed ID: 16917142 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310 [TBL] [Abstract][Full Text] [Related]
13. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079 [TBL] [Abstract][Full Text] [Related]
14. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611 [TBL] [Abstract][Full Text] [Related]
15. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Peng J; Sengupta S; Jordan VC Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291 [TBL] [Abstract][Full Text] [Related]
16. Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells. Gao ZO; Gao ZP; Fields JZ; Boman BM Anticancer Res; 2002; 22(3):1379-83. PubMed ID: 12168814 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway. Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221 [TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444 [TBL] [Abstract][Full Text] [Related]
19. NAMPT regulates PKM2 nuclear location through 14-3-3ζ: Conferring resistance to tamoxifen in breast cancer. Ge X; Zhao Y; Dong L; Seng J; Zhang X; Dou D J Cell Physiol; 2019 Dec; 234(12):23409-23420. PubMed ID: 31141164 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]